OBJECTIVES: The aim of this study was to assess the prognostic value of T-wave alternans (TWA) in New York Heart Association (NYHA) functional class II/III patients with nonischemic cardiomyopathy and left ventricular ejection fraction (LVEF) < or =40%. BACKGROUND: There is a strong need to identify reliable risk stratifiers among heart failure candidates for implantable cardioverter-defibrillator (ICD) prophylaxis. T-wave alternans may identify low-risk subjects among post-myocardial infarction patients with depressed LVEF, but its predictive role in nonischemic cardiomyopathy is unclear. METHODS: Four hundred forty-six patients were enrolled and followed up for 18 to 24 months. The primary end point was the combination of cardiac death + life-threatening arrhythmias; secondary end points were total mortality and the combination of arrhythmic death + life-threatening arrhythmias. RESULTS: Patients with abnormal TWA (65%) compared with normal TWA (35%) tests were older (60 +/- 13 years vs. 57 +/- 12 years), were more frequently in NYHA functional class III (22% vs. 19%), and had a modestly lower LVEF (29 +/- 7% vs. 31 +/- 7%). Primary end point rates in patients with abnormal and normal TWA tests were 6.5% (95% confidence interval [CI] 4.5% to 9.4%) and 1.6% (95% CI 0.6% to 4.4%), respectively. Unadjusted and adjusted hazard ratios were 4.0 (95% CI 1.4% to 11.4%; p = 0.002) and 3.2 (95% CI 1.1% to 9.2%; p = 0.013), respectively. Hazard ratios for total mortality and for arrhythmic death + life-threatening arrhythmias were 4.6 (p = 0.002) and 5.5 (p = 0.004), respectively; 18-month negative predictive values for the 3 end points ranged between 97.3% and 98.6%. CONCLUSIONS: Among NYHA functional class II/III nonischemic cardiomyopathy patients, an abnormal TWA test is associated with a 4-fold higher risk of cardiac death and life-threatening arrhythmias. Patients with normal TWA tests have a very good prognosis and are likely to benefit little from ICD therapy.
OBJECTIVES: The aim of this study was to assess the prognostic value of T-wave alternans (TWA) in New York Heart Association (NYHA) functional class II/III patients with nonischemic cardiomyopathy and left ventricular ejection fraction (LVEF) < or =40%. BACKGROUND: There is a strong need to identify reliable risk stratifiers among heart failure candidates for implantable cardioverter-defibrillator (ICD) prophylaxis. T-wave alternans may identify low-risk subjects among post-myocardial infarctionpatients with depressed LVEF, but its predictive role in nonischemic cardiomyopathy is unclear. METHODS: Four hundred forty-six patients were enrolled and followed up for 18 to 24 months. The primary end point was the combination of cardiac death + life-threatening arrhythmias; secondary end points were total mortality and the combination of arrhythmic death + life-threatening arrhythmias. RESULTS:Patients with abnormal TWA (65%) compared with normal TWA (35%) tests were older (60 +/- 13 years vs. 57 +/- 12 years), were more frequently in NYHA functional class III (22% vs. 19%), and had a modestly lower LVEF (29 +/- 7% vs. 31 +/- 7%). Primary end point rates in patients with abnormal and normal TWA tests were 6.5% (95% confidence interval [CI] 4.5% to 9.4%) and 1.6% (95% CI 0.6% to 4.4%), respectively. Unadjusted and adjusted hazard ratios were 4.0 (95% CI 1.4% to 11.4%; p = 0.002) and 3.2 (95% CI 1.1% to 9.2%; p = 0.013), respectively. Hazard ratios for total mortality and for arrhythmic death + life-threatening arrhythmias were 4.6 (p = 0.002) and 5.5 (p = 0.004), respectively; 18-month negative predictive values for the 3 end points ranged between 97.3% and 98.6%. CONCLUSIONS: Among NYHA functional class II/III nonischemic cardiomyopathypatients, an abnormal TWA test is associated with a 4-fold higher risk of cardiac death and life-threatening arrhythmias. Patients with normal TWA tests have a very good prognosis and are likely to benefit little from ICD therapy.
Authors: Faisal M Merchant; Takanori Ikeda; Roberto F E Pedretti; Jorge A Salerno-Uriarte; Theodore Chow; Paul S Chan; Cheryl Bartone; Stefan H Hohnloser; Richard J Cohen; Antonis A Armoundas Journal: Heart Rhythm Date: 2012-03-08 Impact factor: 6.343
Authors: Sunil Kapur; Gary L Aistrup; Rohan Sharma; James E Kelly; Rishi Arora; Jiabo Zheng; Mitra Veramasuneni; Alan H Kadish; C William Balke; J Andrew Wasserstrom Journal: Am J Physiol Heart Circ Physiol Date: 2010-10-01 Impact factor: 4.733
Authors: Leonardo Calò; Tiziana De Santo; Francesca Nuccio; Luigi Sciarra; Lucia De Luca; Lorenza Mangoni di S Stefano; Enrico Piroli; Lorenzo Zuccaro; Marco Rebecchi; Ermenegildo de Ruvo; Ernesto Lioy Journal: Ann Noninvasive Electrocardiol Date: 2011-10 Impact factor: 1.468
Authors: Euler de Vilhena Garcia; Nelson Samesima; Horácio G Pereira Filho; Cristina M Quadros; Luis Tenório Cavalcante da Silva; Martino Martinelli Filho; Maria Luciana Zacharias Hannouche; Wilson Mathias; Carlos Alberto Pastore Journal: Ann Noninvasive Electrocardiol Date: 2009-04 Impact factor: 1.468
Authors: Eiran Z Gorodeski; Daniel J Cantillon; Sachin S Goel; Elizabeth S Kaufman; David O Martin; Eileen M Hsich; Eugene H Blackstone; Michael S Lauer Journal: J Heart Lung Transplant Date: 2009-05-13 Impact factor: 10.247
Authors: Faisal M Merchant; Hui Zheng; Thomas Bigger; Richard Steinman; Takanori Ikeda; Roberto F E Pedretti; Jorge A Salerno-Uriarte; Catherine Klersy; Paul S Chan; Cheryl Bartone; Stefan H Hohnloser; Jeremy N Ruskin; Antonis A Armoundas Journal: Am Heart J Date: 2013-09-18 Impact factor: 4.749